LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Coumarin-pyrazoline hybrids as selective inhibitors of the tumor-associated carbonic anhydrase IX and XII.

Photo from wikipedia

AIM Human carbonic anhydrase (CA, EC 4.2.1.1) isoforms IX and XII are validated antitumor/antimetastatic drug and tumor imaging targets with sulfonamide inhibitors and monoclonal antibodies in clinical development. Coumarins act… Click to show full abstract

AIM Human carbonic anhydrase (CA, EC 4.2.1.1) isoforms IX and XII are validated antitumor/antimetastatic drug and tumor imaging targets with sulfonamide inhibitors and monoclonal antibodies in clinical development. Coumarins act as isoform-selective inhibitors of these isoforms over the cytosolic and mitochondrial ones. MATERIALS AND METHODS We report the synthesis and in vitro CA inhibitory evaluation of a large panel of coumarins incorporating pyrazole-1-carboxamide moieties. Compounds were fully characterized before the assessment of their inhibitory activity. A stopped-flow CO2 hydrase assay was performed for the biological test. RESULTS These coumarins did not inhibit the widespread, off-target isoforms CA I and II (KI 50 μM), but they were sub-micromolar CA IX/XII inhibitors with an interesting selectivity index higher than the reference compound. Selectivity between α- and β-class of CAs was also promising. CONCLUSION These compounds may be used as leads for the rational design and development of non-sulfonamide CA IX/XII effective inhibitors.

Keywords: xii; carbonic anhydrase; selective inhibitors; coumarin pyrazoline; pyrazoline hybrids

Journal Title: Anti-cancer agents in medicinal chemistry
Year Published: 2023

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.